Meredith Buxton

Meredith Buxton, Ph.D., M.P.H.

Chief Executive Officer

Dr. Buxton has been involved in clinical research and drug development for over 20 years. She has been instrumental in the establishment of numerous innovative clinical research programs, with extensive experience in building and running master protocols and adaptive platform trials. Focused on improved and efficient approaches to the design and execution of clinical trials, Dr. Buxton brings expertise in scientific and operational implementation, regulatory strategy, partnership development, and consortium building.

Before joining GCAR, Dr. Buxton spent almost 15 years at University of California, San Francisco (UCSF) and was an Assistant Professor in the Department of Surgery (Breast Care Center). She was Executive Director of the I-SPY TRIALs Consortium, a series of standing trials (Phase 1 – 3) established to use scientific innovation to guide the use of new agents for women with locally advanced breast cancer. The centerpiece of the Consortium included, I-SPY 2, a phase 2 response adaptive randomization platform trial considered the seminal adaptive platform trial in oncology. Dr. Buxton led the operational team that launched I-SPY 2 and ran operations for over 10 years, testing 10 investigational drugs from 7 pharmaceutical companies. During her tenure at UCSF, she also was Director of Clinical Research for the Breast Care Center and Director of the Postbaccalaureate (Endowed) Internship Program.

Previously, Dr. Buxton was Director of Clinical Trial Strategy at Berry Consultants, where she provided strategic guidance and implementation expertise for several master protocols by industry and nonprofit sponsors from 2017-2018.

Dr. Buxton earned an undergraduate degree at Stanford University and completed a Master’s in Public Health and PhD in Epidemiology from Columbia University. Dr. Buxton also served for 5 years as the Managing Editor of the Journal of the American Medical Women’s Association, a peer-reviewed medical journal focused on women’s health issues.